Comparative Pharmacology
Head-to-head clinical analysis: FLOROPRYL versus PHOSPHOLINE IODIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOROPRYL versus PHOSPHOLINE IODIDE.
FLOROPRYL vs PHOSPHOLINE IODIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible inhibition of monoamine oxidase (MAO) type B, leading to increased levels of dopamine in the brain.
Irreversible acetylcholinesterase inhibitor, increasing acetylcholine at muscarinic and nicotinic receptors.
Not applicable: FLOROPRYL is an investigational drug with no established dosing.
0.125% to 0.25% solution, 1 drop in the affected eye(s) every 12 to 24 hours; maximum 0.25% solution twice daily.
None Documented
None Documented
Terminal half-life 8-12 hours; prolonged to 20-30 hours in renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 1-2 hours; clinical effect outlasts plasma levels due to irreversible acetylcholinesterase inhibition.
Renal: 80-90% unchanged; fecal: <5% as metabolites.
Renal: primarily unchanged drug and metabolites; fecal: minimal. Exact percentages not established.
Category C
Category C
Cholinesterase Inhibitor (Ophthalmic)
Cholinesterase Inhibitor (Ophthalmic)